The biologics vertical was conceptualized in the year 2009. With the identification of key Biosimilars and helmed by a multi-disciplinary team of over 200 specialists, R&D commenced soon at the Hetero Research Foundation(HRF).
Hetero Biosimilars has enabled the company to join select biotech companies with the capability to develop, manufacture and commercialize complex monoclonal antibodies (mABs).
Hetero has successfully launched Biosimilars of Darbepoetin alfa, Rituximab, Bevacizumab and Adalimumab and also has an ambitious pipeline of other Biosimilars.
With this strength in Biosimilars "ASRA" division was carved out to serve the patients in need of Biosimilars for treating rheumatologic conditions.
Over 2000 patients in India in the field of Rheumatology & Dermatolgy, are benefited by MABURA & MABAL-RA Biosimilars of Adalimumab and Rituximab and still going strong.